Transplantation: Sirolimus for secondary SCC prevention in renal transplantation (Q95424606)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

title

Transplantation: Sirolimus for secondary SCC prevention in renal transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

author name string

Fabian Halleck

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

publication date

2 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Nephrology

25 May 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

page(s)

687-689

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

Skin cancer in organ transplant recipients--where do we stand today?

25 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.216

An evaluation of sirolimus in renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.216

Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.216

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.216

Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.216

Sirolimus and secondary skin-cancer prevention in kidney transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.216

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.216

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.216

Sirolimus for calcineurin inhibitors in organ transplantation: contra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.216

31 March 2020

Identifiers

DOI

10.1038/NRNEPH.2012.216

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23026948%20AND%20SRC:MED&resulttype=core&format=json

25 May 2020

1 reference